Dr Gururaj Arumugakani
Telephone:
Location:
- Royal National ENT and Eastman Dental Hospitals
GMC/GDC number:
6055399
Professional background
Dr. Gururaj Arumugakani began his Allergy and Immunology training in 2006, gaining his PhD at the University of Leeds, studying the role of B-cells in allergy and other immune mediated conditions. He was a Consultant in Allergy and Immunology at the Leeds Teaching Hospitals NHS Trust since 2016, and moved to UCLH in 2024. He was the clinical governance lead for the Allergy and Clinical Immunology department in Leeds and chaired the Immunoglobulin Panel. He specialises in all aspects of allergy practice including, food allergy, drug allergy, inhalant allergy, venom allergy, urticaria and immunotherapy. He was actively involved in the initial trials of Omalizumab for urticaria and helped pioneer home therapy for urticaria. He also provides expert advice on allergy and immunology blood testing.
Specialties
Research interests
B-cell mediated disorders.
Languages spoken
Tamil
Publications
Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. Gururaj Arumugakani, Sophie J. Stephenson, Darren J. Newton, Andy Rawstron, Paul Emery, Gina M. Doody, Dennis McGonagle, Reuben M. Tooze. The Journal of Immunology May 10, 2017, 1501761.
Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria. Denman S, Smith H, Arumugakani G, Mistry A, Savic S. Clin Exp Dermatol. 2022 Nov;47(11):2002-2005.
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Shields AM, Anantharachagan A, Arumugakani G, et al. Clin Exp Immunol. 2022 Sep 29;209(3):247-258.
Hyper-IgM syndrome resulting from heterozygous AICDA variants: A European first? Kacar M, Shrimpton JK, Jassam M, Mistry A, Arumugakani G, Grammatikos A, Gompels M, Doody GM, Savic S. Scand J Immunol. 2022 Jul;96(1):e13155.
Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency. Abolhassani H, El-Sherbiny YM, Arumugakani G, Carter C, Richards S, Lawless D, Wood P, Buckland M, Heydarzadeh M, Aghamohammadi A, Hambleton S, Hammarström L, Burns SO, Doffinger R, Savic S. J Clin Immunol. 2020 Feb;40(2):277-288.
Clinical and laboratory features of seventy-eight UK patients with Good's syndrome (thymoma and hypogammaglobulinaemia). Zaman M, Huissoon A, Buckland M, Patel S, Alachkar H, Edgar JD, Thomas M, Arumugakani G, Baxendale H, Burns S, Williams AP, Jolles S, Herriot R, Sargur RB, Arkwright PD. Clin Exp Immunol. 2019 Jan;195(1):132-138.
Reduced human transitional B cell T1/T2 ratio is associated with subsequent deterioration in renal allograft function. Cherukuri A, Salama AD, Carter CR, Landsittel D, Arumugakani G, Clark B, Rothstein DM, Baker RJ. Kidney Int. 2017 Jan;91(1):183-195.
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P. Ann Rheum Dis. 2015 Sep;74(9):1734-8.
Abnormal Memory B-cell reconstitution following anti-CD20 therapy for autoimmune diseases predicts clinical relapse. G.Arumugakani, A.Rawstron, R.Tooze, A.Cherukuri, A.Varghese, E.Vital, P.Emery, D.McGonagle. Ann Rheum Dis 2012;71(Suppl3):183.
Identification of the phenotype of repopulating B-cells associated with disease relapse following B-cell depletion therapy in patients with autoimmune disorders. Gururaj Arumugakani, Reuben Tooze, Ed Vital, Dennis McGonagle, Andy Rawstron, Paul Emery. Online 13/09/2011. DOI: 10.1002/cyto.b.20616.
Frequency of Treg Cells Is Reduced in CVID Patients with Autoimmunity and Splenomegaly and Is Associated with Expanded CD21(lo) B Lymphocytes. Arumugakani G, Wood PM, Carter CR. J Clin Immunol. 2010 Mar;30(2):292-300.